Highlights Nykode Therapeutics

Equities

VACC

NO0010714785

Real-time Oslo Bors Other stock markets 03:37:04 2024-05-14 EDT			5-day change	1st Jan Change
14.1 ^NOK	+0.36%		+0.21%	-34.16%

04-19	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
04-19	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	04-19	CI
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	03-21	CI
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	03-19	CI
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	12-14	CI
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-15	CI
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	23-09-28	CI
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	23-09-20	CI
Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer	23-09-04	CI
Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Nykode Adds New Cancer Vaccine Candidate in Clinical Trial Tie-up With Roche	23-06-01	MT
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer	23-05-31	CI
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Nykode Therapeutics AS Announces Positive Final Results from its Phase 2 Trial of VB10.16 in Combination with PD-L1 Inhibitor Atezolizumab in Advanced Cervical Cancer	23-04-18	CI
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-27	CI
Nykode Therapeutics to Launch US Clinical Trial for Cervical Cancer Treatment	23-02-10	MT
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer	23-02-10	CI
Nykode Expands Clinical Development Plan for Its Lead Cancer Vaccine Vb10.16 in Hpv16-Positive Cancers	22-12-20	CI
Nykode Therapeutics Taps Plasmid DNA Supplier For Vaccine Development	22-12-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nykode Therapeutics

Equities

VACC

NO0010714785

Highlights

Filters